BR9910640A - Compostos possuindo propriedades que afetam aige - Google Patents

Compostos possuindo propriedades que afetam aige

Info

Publication number
BR9910640A
BR9910640A BR9910640-0A BR9910640A BR9910640A BR 9910640 A BR9910640 A BR 9910640A BR 9910640 A BR9910640 A BR 9910640A BR 9910640 A BR9910640 A BR 9910640A
Authority
BR
Brazil
Prior art keywords
aige
affect
compounds
properties
ige
Prior art date
Application number
BR9910640-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jagadish Sircar
Mark L Richards
Michael G Campbell
Michaelw Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9910640(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BR9910640A publication Critical patent/BR9910640A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR9910640-0A 1998-05-22 1999-05-21 Compostos possuindo propriedades que afetam aige BR9910640A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011363 WO1999061013A2 (en) 1998-05-22 1999-05-21 COMPOUNDS HAVING IgE AFFECTING PROPERTIES

Publications (1)

Publication Number Publication Date
BR9910640A true BR9910640A (pt) 2001-10-30

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
BR9910640-0A BR9910640A (pt) 1998-05-22 1999-05-21 Compostos possuindo propriedades que afetam aige
BR9910642-6A BR9910642A (pt) 1998-05-22 1999-05-21 Análogos de benzimidazol como reguladores descendentes de ige
BR9910641-8A BR9910641A (pt) 1998-05-22 1999-05-21 Derivados de benzimidazol como moduladores de ige

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR9910642-6A BR9910642A (pt) 1998-05-22 1999-05-21 Análogos de benzimidazol como reguladores descendentes de ige
BR9910641-8A BR9910641A (pt) 1998-05-22 1999-05-21 Derivados de benzimidazol como moduladores de ige

Country Status (22)

Country Link
US (2) US6271390B1 (https=)
EP (3) EP1079830A1 (https=)
JP (3) JP2002516274A (https=)
KR (1) KR100591652B1 (https=)
CN (4) CN1311675A (https=)
AT (1) ATE292465T1 (https=)
AU (3) AU754943B2 (https=)
BR (3) BR9910640A (https=)
CA (3) CA2332985A1 (https=)
CZ (2) CZ20004351A3 (https=)
DE (1) DE69924607T2 (https=)
ES (1) ES2241285T3 (https=)
HU (3) HUP0102128A3 (https=)
IL (3) IL139826A0 (https=)
MX (3) MXPA00011470A (https=)
NO (3) NO20005889L (https=)
NZ (2) NZ508413A (https=)
PL (3) PL345219A1 (https=)
RU (2) RU2236220C2 (https=)
UA (2) UA67774C2 (https=)
WO (3) WO1999061020A1 (https=)
ZA (3) ZA200007754B (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2236220C2 (ru) * 1998-05-22 2004-09-20 Аванир Фармасьютикэлз Аналоги бензимидазола в качестве понижающих регуляторов ige
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
KR20010079782A (ko) * 1998-09-11 2001-08-22 에가시라 구니오 벤젠 유도체 및 이의 의약 용도
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
CA2368631A1 (en) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
JP4609691B2 (ja) * 1999-07-01 2011-01-12 味の素株式会社 複素環化合物及びその医薬用途
EP1211240A4 (en) 1999-09-01 2003-02-12 Ajinomoto Kk BISCYCLOPROPANOCARBOXYLIC ACID AMIDE COMPOUNDS AND MEDICINAL USE THEREOF
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP4658473B2 (ja) * 2001-07-27 2011-03-23 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
EP1435947B1 (en) 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
PT2527315E (pt) 2002-05-31 2014-06-24 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004041280A1 (en) * 2002-11-02 2004-05-21 Kyung-Lim Lee Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
HRP20130971T1 (hr) 2004-02-20 2013-11-08 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
BRPI0510803A (pt) * 2004-05-12 2007-11-06 Proteotech Inc composto, composição farmacêutica, artigo de fabricação, métodos de tratar ou prevenir a formação, deposição, acúmulo ou persistência de fibrilas de amilóide e de fibrilas de sinucleìna, e de tratar, prevenir ou melhorar um ou mais sintomas de uma doença amilóide ou uma sinucleinopatia em um mamìfero, e, uso do composto
EP1824832B1 (en) 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US8334290B2 (en) † 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
JP5690839B2 (ja) * 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
KR20130091729A (ko) * 2010-07-20 2013-08-19 베스타론 코포레이션 살충제 트라이아진 및 피리미딘
EP2632915B1 (en) 2010-10-29 2015-08-12 Boehringer Ingelheim International GmbH Benzimidazole inhibitors of leukotriene production
JP5789888B2 (ja) 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
IL281427B2 (en) * 2018-09-18 2026-01-01 Terns Inc Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DE69113162T2 (de) * 1990-08-02 1996-03-14 Hoffmann La Roche Antiallergische Mischung.
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP3634861B2 (ja) * 1992-06-15 2005-03-30 セルテック リミテッド 選択的ホスホジエステラーゼｉｖ阻害剤としての三置換フェニル誘導体
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
RU2236220C2 (ru) * 1998-05-22 2004-09-20 Аванир Фармасьютикэлз Аналоги бензимидазола в качестве понижающих регуляторов ige
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
US7072848B2 (en) * 2000-11-15 2006-07-04 Manugistics, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
HUP0102550A3 (en) 2002-11-28
CA2332999A1 (en) 1999-12-02
AU4197899A (en) 1999-12-13
UA67775C2 (uk) 2004-07-15
NO20005889L (no) 2001-01-22
CN1311675A (zh) 2001-09-05
CN1311679A (zh) 2001-09-05
EP1077695A2 (en) 2001-02-28
AU754943B2 (en) 2002-11-28
JP2002516277A (ja) 2002-06-04
CN1317965A (zh) 2001-10-17
CZ20004351A3 (cs) 2001-10-17
JP2002516274A (ja) 2002-06-04
BR9910642A (pt) 2001-10-09
US6271390B1 (en) 2001-08-07
ATE292465T1 (de) 2005-04-15
CN1721411A (zh) 2006-01-18
MXPA00011470A (es) 2002-10-17
CZ20004350A3 (cs) 2002-02-13
NZ508413A (en) 2003-08-29
MXPA00011467A (es) 2002-10-17
AU754562B2 (en) 2002-11-21
ZA200007754B (en) 2001-08-16
IL139827A0 (en) 2002-02-10
NO20005888L (no) 2001-01-22
UA67774C2 (uk) 2004-07-15
PL345560A1 (en) 2001-12-17
JP2002516276A (ja) 2002-06-04
CN1219510C (zh) 2005-09-21
CA2332989A1 (en) 1999-12-02
CA2332985A1 (en) 1999-12-02
IL139828A0 (en) 2002-02-10
DE69924607T2 (de) 2006-02-02
AU4312099A (en) 1999-12-13
IL139826A0 (en) 2002-02-10
NZ508416A (en) 2004-01-30
HUP0101894A2 (hu) 2002-02-28
HUP0102128A3 (en) 2002-05-28
WO1999061019A1 (en) 1999-12-02
BR9910641A (pt) 2001-10-02
HUP0101894A3 (en) 2002-07-29
WO1999061020A1 (en) 1999-12-02
US20020010343A1 (en) 2002-01-24
AU4094299A (en) 1999-12-13
NO20005888D0 (no) 2000-11-21
US6451829B2 (en) 2002-09-17
WO1999061013A2 (en) 1999-12-02
NO20005887L (no) 2001-01-19
EP1079830A1 (en) 2001-03-07
DE69924607D1 (de) 2005-05-12
PL345952A1 (en) 2002-01-14
HUP0102550A2 (hu) 2001-10-28
KR20010030179A (ko) 2001-04-16
RU2236221C2 (ru) 2004-09-20
NO20005889D0 (no) 2000-11-21
ES2241285T3 (es) 2005-10-16
HUP0102128A2 (hu) 2002-03-28
KR100591652B1 (ko) 2006-06-26
RU2236220C2 (ru) 2004-09-20
PL345219A1 (en) 2001-12-03
WO1999061013A3 (en) 2000-04-06
EP1077700B1 (en) 2005-04-06
NO20005887D0 (no) 2000-11-21
MXPA00011422A (es) 2002-12-13
ZA200007752B (en) 2001-12-05
ZA200007753B (en) 2001-07-18
EP1077700A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
BR9910640A (pt) Compostos possuindo propriedades que afetam aige
BR0208010A (pt) Composto de benzimidazol para modulação de ige e inibição de proliferação celular
BR0314235A (pt) Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular
BR0110993A (pt) Composto, composição farmacêutica compreendendo o mesmo e método
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
NO20041160L (no) Bio-avlesningsplattform for pavisning og kvantitering av biologiske molekyler
DE60216122D1 (de) Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
BR9909248A (pt) Inibidores de enzima
ATE278384T1 (de) Zusammensetzung, insbensodere für kosmetika, enthaltend dhea und/oder einen chemische oder biologische vorläufer davon und einen metalloproteinase inhibitor
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
BR0200921A (pt) Uso de produtos de legume para o tratamento de agressões externas
DE69801661D1 (de) Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten
BR9911785A (pt) Combinações de farnesil transferase de proteìna e inibidores de redutase de hmg coa e seu uso para tratar câncer
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
ES2163691T3 (es) Revestimiento de suelo y procedimiento para su fabricacion.
PT1603544E (pt) Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina
DK1236402T3 (da) Sammensætninger indeholdende sojaprodukter
BRPI0411094A (pt) produto de madeira e método para o mesmo
ATE522601T1 (de) Varianten von antithrombin iii
DE69609510D1 (de) Bispezifische moleküle gegen allergie
BR0101985A (pt) Extrato de gérmen de arroz
DE69104067D1 (de) Pyrimido-benzothiazine mit Lipoxygenase-hemmung.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.